Christmas cheer: Interim reports of PPHM's Bavituximab indicate a subset of Liver cancers...probably 1/4-1/3 of them... appear to be uniquely responsive to Bavituximab + Sorafemib, producing increased immune cell infiltrates into the cancers which produce and deliver the patient's own cancer killers. "If this trend continues", as pundits say on election night, Bavituximab will be approved for Liver cancer, and probably for that subset of liver cancers (Millions of patients worldwide) associated most closely with subacute (e.g., active) hepatitis virus.
Bavituximab, a moderate immune stimulant when used as a "naked" (e.g. unarmed) antibody, will eventually be used in early cancers, those smaller than 1cm (<1/2 inch), which is the size we are now able to diagnose precisely. Extensive preclinical and human trial data confirm Bavituximab almost certain safety extends the "degrees of freedom" in its use to much more than just cancer cases. The list of possible applications anti-lipoprotein antibodies such as Bavituximab and similar, seems vast at this point, is similar to the craze now for anti-oxidants, but much more potent, specific, and/or "directed" treatment than antioxidants.
Obviously, an intact immune system, unpoisoned by "chemotherapeutics" (e.g. cytotoxins), is a plus... yet Bavituximab is currently in clinical trials against end-stage lung cancer, and also advanced "untreated" liver cancer ("untreated", wink-wink). Bulky, solid tumors.
For those who feel robbed by the apparently sabotaged early trials, this is obviously the time for you to fund your feelings and buy at bargain prices. You have been spared the agony of jumping in at a much higher price after two years of almost priceless increased knowledge about Bavituximab's potential, and its mode of action. Cheers everyone. Off for dinner now. I am frustrated too, but generally optimistic.
